Like cholesterol, inflammation causally contributes to the risk of cardiovascular disease, but findings from the clinical trial ZEUS indicate that the road to targeting inflammation may be less straightforward than once thought. ZEUS, a global phase 3 clinical trial led by Mass General Brigham researcher Paul Ridker, M.D., tested a drug that targets interleukin-6 (IL-6), a downstream inflammatory…
Former Minister for Finance, Ken Ofori-Atta, has paid a glowing tribute to the late Dr Isaac Akuetteh Bampoe Addo, describing the former Executive Secretary of the Civil and Local Government Staff…
The heart drug whose failure knocked 9% off Novo’s share price in July had almost no effect at all in its pivotal trial. And data on a cardiovascular candidate from Novartis ...
Researchers have identified a unique brain connectivity pattern linked to cocaine use disorder. This biological marker can distinguish patients from healthy individuals and predict whether they will…
